Latest Breaking News On - Jonas hannestad - Page 1 : comparemela.com

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson s Disease

BETHESDA, Md., April 24, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule.

Jonas hannestadMatthias alderElio ambrosioNic johnsonSwiss innovation agencyEuropean union horizonExchange commission onCompany annual report on formMichaelj fox foundation for parkinson researchBellberry human research ethics committeeSilverstein foundation for parkinsonExchange commissionGain therapeutics incGain chief medical officer jonasSilverstein foundationSwiss innovation

Gain Therapeutics Announces Positive Results from the

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology.

Jonas hannestadMatthias alderElio ambrosioNic johnsonCompany annual report on formEuropean union horizonSilverstein foundation for parkinsonExchange commission onMichaelj fox foundation for parkinson researchSwiss innovation agencyExchange commissionGain therapeutics incBellberry human research ethics committeeGain chief medical officer jonasSilverstein foundationSwiss innovation

Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jonas hannestadMatthias alderGain therapeutics incSilverstein foundation for parkinsonBellberry human research ethics committeeMichaelj fox foundation for parkinson researchEuropean union horizonSwiss innovation agencyGain therapeuticsGain chief medical officer jonasSilverstein foundationSwiss innovationSite directed enzyme enhancement therapy

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Anitra (AMEX:AZTR)

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Miltonc aultJonas hannestadEric weisblumJeffrey scott rileyAzitra incSilo pharma incGain therapeutics incDow jonesPharma incAlzamend neuro incAlzamend neuroAlzamend neuro doesGain therapeuticsGain therapeutics doesInvestor sentiment improvesDow falls over

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M D , Ph D as Chief Medical Officer

BETHESDA, Md., April 01, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies,.

Elio ambrosioNic johnsonJonas hannestadBristol myers squibbMatthias alderGain therapeutics incNeuropsychiatric instituteExchange commission onCompany annual report on formDuke school of medicineClinical development at alkahestUniversity of oviedoEuropean union horizonMichaelj fox foundation for parkinson researchCompensation committee of gain board directorsSilverstein foundation for parkinson